ClinicalTrials.gg
RecruitingNCT07271667Updated Jun 12, 2026

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

A Phase 2 interventional study of Emavusertib and Zanubrutinib in Chronic Lymphocytic Leukemia and B-cell Malignancies, sponsored by Curis, Inc.. Recruiting at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Curis, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States — 138 open to participants now, 252 under way, 34 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · United States.

Planned enrollment
218th of 1,298
108 · median 36
Started
2026
with 31 others
Phase 2
546 of 1,501
48 open now
Primary completion
2027-11
later than 144 of 248 live
Registered
1,475th of 1,501
by date

Among the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, this one is the 218th largest by planned enrollment of the 1,298 interventional ones that give a count, is one of 32 that started in 2026, is one of 546 in phase 2, reaches primary completion later than 144 of the 248 other live ones, and was the 1,475th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

138 of the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States are open now. Recruiting first, the newest first:

132 more — sign in →

All 138 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • B-cell Malignancies

Keywords

  • Emavusertib
  • BTKi
  • B-cell Malignancies
  • Chronic Lymphocytic Leukemia
  • CLL
  • Zanubrutinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females ≥ 18 years of age.
  2. of ≥ 3 months.
  3. Performance Status of 0, 1, or 2.
  4. Histopathologically confirmed diagnosis of CLL (medical record is acceptable), as per the World Health Organization 2016 classification.
  5. At least 1 criterion for per International Workshop on Chronic Lymphocytic Leukemia (iwCLL).
  6. For Cohort 1 only:

    1. Participant must be in a partial response (PR) or partial response with lymphocytosis (PR-L) and measurable residual disease positive (MRD+) per Hallek et al, (2018) criteria.
    2. Participant must have detectable measurable residual disease (MRD) as determined by the ClonoSEQ assay
    3. Must be actively taking zanubrutinib for at least 12 months.
    4. Acceptable organ function at Screening within 28 days prior to Cycle 1 Day 1 (C1D1)
  7. For Cohort 2 only:

    1. disease for which participants are ineligible for or have exhausted standard therapeutic options that would be considered standard of care
    2. Must be actively taking zanubrutinib.
    3. Participants must have had direct progression on zanubrutinib (within 3 months prior to study entry; administered as monotherapy or in combination) and no other anticancer therapy administered since.
    4. Acceptable organ function at Screening within 28 days prior to C1D1.
  8. Creatine phosphokinase (CPK) \< 2.5 × .
  9. Ability to tolerate a contrast-enhanced computed tomography (CT) scan.
  10. Ability to swallow and retain oral medications.
  11. Negative serum pregnancy test in women of (WOCP).
  12. WOCP and men who partner with WOCP must agree to use highly effective methods for the duration of the study and for 180 days after the last dose of study treatment.
  13. Ability to understand and willingness to sign a written document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion criteria

Exclusion Criteria (All Parts):

  1. Active second unless in remission with a of > 2 years and with documented Sponsor approval.
  2. Active malignancy other than CLL requiring systemic therapy (exceptions may be granted following a discussion with the Sponsor Medical Monitor).
  3. Have high-risk CLL TP53 mutations and 17P deletion.
  4. History of Grade ≥ 3 rhabdomyolysis without complete recovery.
  5. Received prior chimeric antigen receptor-T cell therapy.
  6. Received prior drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, prior to C1D1; hematopoietic stem cell transplant (HSCT) within 60 days prior to C1D1; or had (GVHD) requiring ongoing uptitration of medications prior to Screening.
  7. Any prior systemic anticancer treatment such as chemotherapy, immunomodulatory drug therapy, etc., received within 21 days or 5 half-lives, whichever is shorter, prior to C1D1 (with the exception of zanubrutinib, which may be continued until the day before C1D1).
  8. Receiving the following medications within 7 days or 5 half-lives, whichever is shorter, prior to C1D1:

    1. Medications that, in the opinion of the Investigator, have a high risk of causing prolonged , corrected (QTc) and/or Torsades de Pointes.
    2. Peg-filgrastim or equivalent.
    3. St John's Wort.
  9. History of or ongoing drug-induced pneumonitis.
  10. History of stroke or intracranial hemorrhage within 6 months prior to C1D1. Participants with post- hemorrhagic sequela defined as a small hyperdense lesion \< 3 millimeters (mm) on T2 sequence will not be excluded.
  11. Requirement for anticoagulation with warfarin or equivalent vitamin K antagonists, including dual antiplatelet agents, within 5 half-lives of the anticoagulant or 7 days, whichever is longer, prior to C1D1. Low molecular weight heparin is allowed. Participants who require the use of antiplatelet agents should be discussed with the Sponsor Medical Monitor (e.g., use of factor Xa inhibitors).
  12. Vaccinated with a within 4 weeks prior to C1D1.
  13. Prior history of or anaphylaxis to emavusertib, zanubrutinib, or any of their .
  14. Prior history of Stevens-Johnson syndrome or toxic epidermal necrolysis.
  15. Intolerance to contrast-enhanced CT scan due to allergic reactions to contrast agents.
  16. Major surgery \< 28 days prior to C1D1; minor surgery \< 7 days prior to C1D1.
  17. Viral infections:

    1. Known to be (HIV) positive or have an acquired immunodeficiency syndrome (AIDS)-related illness. If HIV is undetectable or maintained on treatment, enrollment may be allowed after discussion with the Sponsor Medical Monitor.
    2. virus (HBV) deoxyribonucleic acid (DNA) positive or virus (HCV) infection \< 6 months prior to C1D1, unless viral load is undetectable, or HCV with cirrhosis.
    3. Active systemic infection, including HIV, cytomegalovirus infection, or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, or has had, within 28 days prior to C1D1, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic.
  18. Concomitant illness that would preclude safe participation in the study.
  19. Pregnant or lactating female.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Emavusertib and Zanubrutinib

    Participants in Cohort 1 include CLL participants who have been on zanubrutinib for at least 12 months and are currently in a partial response (PR) or partial response with lymphocytosis (PR-L) and measurable residual disease positive (MRD+). In Part A, participants will receive one of two doses of emavusertib twice daily (BID) and an approved dose of zanubrutinib per label. In Part B, additional participants will be enrolled in an expansion if pre-defined criteria for Part A are met. Participants will receive one of two doses of emavusertib BID and an approved dose of zanubrutinib per label.

    Drug: Emavusertib · Drug: Zanubrutinib

  • Experimental
    Cohort 2: Emavusertib and Zanubrutinib

    Participants in Cohort 2 include relapsed CLL participants who have directly progressed on zanubrutinib after a confirmed response (PR or better lasting 6 months or longer). In Part A, participants will receive one of two doses of emavusertib BID and an approved dose of zanubrutinib per label. In Part B, additional participants will be enrolled in an expansion if pre-defined criteria for Part A are met. Participants will receive one of two doses of emavusertib BID and an approved dose of zanubrutinib per label.

    Drug: Emavusertib · Drug: Zanubrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Cohort 1: Undetectable Measurable Residual Disease (uMRD) Rate

    Time frame: Up to approximately 23 months

  2. Cohort 2: Overall Response Rate (ORR)

    Time frame: Up to approximately 23 months

Secondary outcomes

  1. Cohort 1: Duration of uMRD

    Time frame: Up to approximately 23 months

  2. Cohort 1: Time to Measurable Residual Disease (MRD) Conversion

    Time frame: Up to approximately 23 months

  3. Cohort 1: Complete Response (CR) Rate

    Time frame: Up to approximately 23 months

  4. Cohort 1: Duration of CR

    Time frame: Up to approximately 23 months

  5. Cohort 1: Time to CR

    Time frame: Up to approximately 23 months

  6. Cohort 2: Duration of Response (DOR)

    Time frame: Up to approximately 23 months

  7. Cohort 2: Time to Response

    Time frame: Up to approximately 23 months

  8. Cohorts 1 and 2: Progression-free Survival (PFS)

    Time frame: Up to approximately 23 months

  9. Cohorts 1 and 2: Overall Survival (OS)

    Time frame: Up to approximately 23 months

  10. Cohorts 1 and 2: Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Treatment-related Adverse Events

    Time frame: Up to approximately 23 months

  11. Cohorts 1 and 2: Maximum Plasma Concentration (Cmax) of Emavusertib and Zanubrutinib

    Time frame: Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle = 28 days)

  12. Cohorts 1 and 2: Time to Maximum Concentration (Tmax) of Emavusertib and Zanubrutinib

    Time frame: Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle = 28 days)

  13. Cohorts 1 and 2: Area Under the Curve (AUC) from 0 to t Hours (AUC0-t) of Emavusertib and Zanubrutinib

    Time frame: Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle = 28 days)

  14. Cohorts 1 and 2: Trough Plasma Concentration (Cmin) of Emavusertib and Zanubrutinib

    Time frame: Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle = 28 days)

07

Study locations

11 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2027, 19 months after the start.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's planned 19 months is below that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2025
First posted
Dec 9, 2025
StartActual
Apr 23, 2026
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07271667
Lead sponsor
Curis, Inc.
Responsible party
Sponsor
First posted
Dec 9, 2025
Start date
Apr 23, 2026
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jun 12, 2026

Study contacts

Ahmed Hamdy, MD
Contact
clinicaltrials@curis.com
617-503-6500

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CA-4948

Start the discussion